Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
This is a protective physiological response where the body reduces its energy expenditure to conserve resources
Feng, M., Xiong, G., Cao, Z., Yang, G., Zheng, S., Qiu, J., You, L., Zheng, L., Zhang, T., & Zhao, Y
The STEP 1 trial showed semaglutide 2.4 mg led to 14.9% weight loss over 68 weeks, while SURMOUNT-1 showed tirzepatide achieved up to 20.9% weight reductionapproaching bariatric surgery outcomes.[6] The SELECT trial (17,604 patients) found semaglutide reduced cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20% and all-cause mortality by 19%, suggesting direct cardioprotective effects beyond weight loss.[4] In STEP-HFpEF, semaglutide produced 13.3% weight loss in heart failure patients and improved symptoms and physical function
Activin A Blockade Enhances Effect# Adding garetosmab (anti-activin A) to the trevogrumab + semaglutide combination substantially increased lean mass preservation from ~51% to 80.9%, supporting the concept that both myostatin and activin A must be blocked for maximal muscle preservation
US$ 20.56
US$ 28.73
US$ 28.83
US$ 22.28
US$ 24.17
